The results demonstrated that the combination therapies induced marked tumor growth suppression for more than 1 month, suggesting that brigatinib with any of the anti-EGFR antibodies is effective against osimertinib-resistant EGFR-del19/C797S or -del19/T790M/C797S tumors. The gene discussed is EGFR; the disease is neoplasm.